Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Ovid Therapeutics to post earnings of ($0.10) per share and revenue of $0.0630 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Ovid Therapeutics Trading Up 3.2%

Shares of NASDAQ:OVID opened at $1.91 on Friday. The firm has a fifty day moving average of $1.61 and a two-hundred day moving average of $1.50. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.28. Ovid Therapeutics has a 12-month low of $0.24 and a 12-month high of $2.01. The firm has a market capitalization of $136.01 million, a P/E ratio of -3.82 and a beta of 0.25.

Hedge Funds Weigh In On Ovid Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of OVID. Invesco Ltd. acquired a new position in Ovid Therapeutics during the 4th quarter valued at $54,000. ADAR1 Capital Management LLC increased its holdings in shares of Ovid Therapeutics by 33,256.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company’s stock worth $6,985,000 after purchasing an additional 4,272,154 shares during the period. Quadrature Capital Ltd raised its position in shares of Ovid Therapeutics by 217.2% during the fourth quarter. Quadrature Capital Ltd now owns 87,874 shares of the company’s stock valued at $143,000 after buying an additional 60,171 shares during the last quarter. Millennium Management LLC raised its position in shares of Ovid Therapeutics by 35.8% during the fourth quarter. Millennium Management LLC now owns 1,339,465 shares of the company’s stock valued at $2,183,000 after buying an additional 353,172 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Ovid Therapeutics in the fourth quarter valued at about $2,910,000. Institutional investors own 72.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on OVID shares. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Ovid Therapeutics in a report on Monday, December 22nd. Leerink Partners began coverage on Ovid Therapeutics in a research report on Monday, November 17th. They set an “outperform” rating and a $5.00 target price for the company. Wall Street Zen downgraded Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Thursday, January 22nd. Finally, Roth Mkm assumed coverage on shares of Ovid Therapeutics in a research note on Thursday, December 11th. They issued a “buy” rating and a $3.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $3.88.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.